Description: Neurizon Therapeutics Limited, a clinical stage biotechnology company, develops therapeutics for neurodegenerative diseases in Switzerland, Australia, the United States, and internationally. The company develops drug discovery intellectual property for the treatment of various cancers and neurological diseases. Its lead candidate is Monepantel (MPL), a small molecule drug which is in Phase II clinical trials for the treatment of amyotrophic lateral sclerosis, as well as to treat other neurodegenerative diseases, such as Alzheimer's and Parkinson's disease. The company was formerly known as PharmAust Limited and changed its name to Neurizon Therapeutics Limited in October 2024. Neurizon Therapeutics Limited was incorporated in 2000 and is based in Melbourne, Australia.
Home Page: www.neurizon.com
96-100 Albert Road
Melbourne,
VIC
3205
Australia
Phone:
61 3 9692 7222
Officers
| Name | Title |
|---|---|
| Dr. Michael Thurn Ph.D. | MD, CEO & Director |
| Mr. John Clark | Chief Operating Officer |
| Dr. Nicky Wallis | Chief Scientific Officer |
| Ms. Fiona Milner | General Manager of Epichem Pty Ltd |
Exchange: AU
Country: AU : Australia
Currency: Australian Dollar (A$)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | June |
| Full Time Employees: | 0 |